HRP20100313T1 - Postupak za određivanje odaziva na chk1 inhibitore - Google Patents
Postupak za određivanje odaziva na chk1 inhibitore Download PDFInfo
- Publication number
- HRP20100313T1 HRP20100313T1 HR20100313T HRP20100313T HRP20100313T1 HR P20100313 T1 HRP20100313 T1 HR P20100313T1 HR 20100313 T HR20100313 T HR 20100313T HR P20100313 T HRP20100313 T HR P20100313T HR P20100313 T1 HRP20100313 T1 HR P20100313T1
- Authority
- HR
- Croatia
- Prior art keywords
- sample
- chk
- phosphorylated
- inhibitor
- determining
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 15
- 239000003112 inhibitor Substances 0.000 title claims abstract 9
- 101150050673 CHK1 gene Proteins 0.000 title claims 14
- 230000004043 responsiveness Effects 0.000 title abstract 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims abstract 7
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims abstract 7
- 239000012623 DNA damaging agent Substances 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 4
- 102100034533 Histone H2AX Human genes 0.000 claims 3
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000000113 radiomimetic effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65413105P | 2005-02-18 | 2005-02-18 | |
| PCT/GB2006/000548 WO2006087557A1 (en) | 2005-02-18 | 2006-02-16 | METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100313T1 true HRP20100313T1 (hr) | 2010-07-31 |
Family
ID=36295309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100313T HRP20100313T1 (hr) | 2005-02-18 | 2010-05-31 | Postupak za određivanje odaziva na chk1 inhibitore |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080145358A1 (de) |
| EP (1) | EP1853721B1 (de) |
| JP (1) | JP2008530575A (de) |
| KR (1) | KR20070107034A (de) |
| CN (1) | CN101120096A (de) |
| AT (1) | ATE464395T1 (de) |
| AU (1) | AU2006215413B2 (de) |
| BR (1) | BRPI0607798A2 (de) |
| CA (1) | CA2598185A1 (de) |
| CY (1) | CY1110076T1 (de) |
| DE (1) | DE602006013604D1 (de) |
| DK (1) | DK1853721T3 (de) |
| ES (1) | ES2341796T3 (de) |
| HK (1) | HK1113059A1 (de) |
| HR (1) | HRP20100313T1 (de) |
| IL (1) | IL184873A0 (de) |
| MX (1) | MX2007010073A (de) |
| NO (1) | NO20074610L (de) |
| NZ (1) | NZ556718A (de) |
| PL (1) | PL1853721T3 (de) |
| PT (1) | PT1853721E (de) |
| SI (1) | SI1853721T1 (de) |
| WO (1) | WO2006087557A1 (de) |
| ZA (1) | ZA200706670B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008064181A2 (en) * | 2006-11-21 | 2008-05-29 | Merial Limited | Prime boost canine leishmania vaccine |
| US8173366B2 (en) | 2007-03-29 | 2012-05-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer |
| US8263329B2 (en) | 2007-03-29 | 2012-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer |
| GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
| JP5436786B2 (ja) * | 2008-03-06 | 2014-03-05 | オリンパス株式会社 | 細胞周期計測方法 |
| WO2010076887A1 (en) * | 2009-01-05 | 2010-07-08 | Banyu Pharmaceutical Co.,Ltd. | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor |
| WO2016126616A1 (en) | 2015-02-02 | 2016-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax |
| US20190147976A1 (en) * | 2016-05-05 | 2019-05-16 | Nantomics, Llc | Checkpoint failure and methods therefor |
| WO2018030546A1 (ja) * | 2016-08-12 | 2018-02-15 | 日立化成株式会社 | 血中循環癌細胞を検出するための前処理剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001161398A (ja) * | 1999-12-06 | 2001-06-19 | Igaku Seibutsugaku Kenkyusho:Kk | タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット |
| JP3990718B2 (ja) * | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
| JP2006520397A (ja) * | 2003-03-14 | 2006-09-07 | アストラゼネカ アクチボラグ | 新規融合トリアゾロン類及びその使用 |
| JP4597976B2 (ja) * | 2003-04-17 | 2010-12-15 | アルナイラム ファーマシューティカルズ インコーポレイテッド | 修飾ｉＲＮＡ剤 |
| ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
| US20050207998A1 (en) * | 2003-07-21 | 2005-09-22 | Yaoping Lu | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer |
| AU2004274013A1 (en) * | 2003-09-17 | 2005-03-31 | Icos Corporation | Use of Chk1 inhibitors to control cell proliferation |
-
2006
- 2006-02-16 ES ES06709785T patent/ES2341796T3/es active Active
- 2006-02-16 PT PT06709785T patent/PT1853721E/pt unknown
- 2006-02-16 AU AU2006215413A patent/AU2006215413B2/en not_active Ceased
- 2006-02-16 EP EP06709785A patent/EP1853721B1/de active Active
- 2006-02-16 JP JP2007555699A patent/JP2008530575A/ja active Pending
- 2006-02-16 PL PL06709785T patent/PL1853721T3/pl unknown
- 2006-02-16 US US11/816,128 patent/US20080145358A1/en not_active Abandoned
- 2006-02-16 AT AT06709785T patent/ATE464395T1/de active
- 2006-02-16 KR KR1020077018373A patent/KR20070107034A/ko not_active Application Discontinuation
- 2006-02-16 MX MX2007010073A patent/MX2007010073A/es active IP Right Grant
- 2006-02-16 DE DE602006013604T patent/DE602006013604D1/de active Active
- 2006-02-16 SI SI200630659T patent/SI1853721T1/sl unknown
- 2006-02-16 WO PCT/GB2006/000548 patent/WO2006087557A1/en active Application Filing
- 2006-02-16 NZ NZ556718A patent/NZ556718A/en not_active IP Right Cessation
- 2006-02-16 BR BRPI0607798-6A patent/BRPI0607798A2/pt not_active IP Right Cessation
- 2006-02-16 CN CNA2006800052527A patent/CN101120096A/zh active Pending
- 2006-02-16 CA CA002598185A patent/CA2598185A1/en not_active Abandoned
- 2006-02-16 DK DK06709785.7T patent/DK1853721T3/da active
-
2007
- 2007-07-26 IL IL184873A patent/IL184873A0/en unknown
- 2007-08-10 ZA ZA200706670A patent/ZA200706670B/xx unknown
- 2007-09-11 NO NO20074610A patent/NO20074610L/no not_active Application Discontinuation
-
2008
- 2008-03-03 HK HK08102350.2A patent/HK1113059A1/xx not_active IP Right Cessation
-
2010
- 2010-05-31 HR HR20100313T patent/HRP20100313T1/hr unknown
- 2010-06-09 CY CY20101100544T patent/CY1110076T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101120096A (zh) | 2008-02-06 |
| PL1853721T3 (pl) | 2010-08-31 |
| ZA200706670B (en) | 2008-10-29 |
| MX2007010073A (es) | 2007-10-10 |
| CY1110076T1 (el) | 2015-01-14 |
| DE602006013604D1 (de) | 2010-05-27 |
| EP1853721A1 (de) | 2007-11-14 |
| PT1853721E (pt) | 2010-06-08 |
| BRPI0607798A2 (pt) | 2010-06-22 |
| SI1853721T1 (sl) | 2010-06-30 |
| DK1853721T3 (da) | 2010-06-14 |
| EP1853721B1 (de) | 2010-04-14 |
| IL184873A0 (en) | 2007-12-03 |
| KR20070107034A (ko) | 2007-11-06 |
| US20080145358A1 (en) | 2008-06-19 |
| ES2341796T3 (es) | 2010-06-28 |
| NO20074610L (no) | 2007-11-14 |
| AU2006215413A1 (en) | 2006-08-24 |
| ATE464395T1 (de) | 2010-04-15 |
| AU2006215413B2 (en) | 2010-10-07 |
| NZ556718A (en) | 2010-10-29 |
| HK1113059A1 (en) | 2008-09-19 |
| WO2006087557A1 (en) | 2006-08-24 |
| JP2008530575A (ja) | 2008-08-07 |
| CA2598185A1 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100313T1 (hr) | Postupak za određivanje odaziva na chk1 inhibitore | |
| da Costa et al. | Targeting replication stress in cancer therapy | |
| Sethy et al. | 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition | |
| Candelaria et al. | A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors | |
| Qin et al. | Effect of cytarabine and decitabine in combination in human leukemic cell lines | |
| Coward et al. | Size does matter: why polyploid tumor cells are critical drug targets in the war on cancer | |
| Maslov et al. | 5-aza-2′-deoxycytidine-induced genome rearrangements are mediated by DNMT1 | |
| Koehler et al. | Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition | |
| Månsson et al. | Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance | |
| Heitz et al. | Poly (ADP-ribosyl) ation polymerases: mechanism and new target of anticancer therapy | |
| Gatiac et al. | Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC) | |
| Bergman et al. | Cross-resistance in the 2′, 2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs | |
| Kaur et al. | Identification of Schlafen-11 as a target of CD47 signaling that regulates sensitivity to ionizing radiation and topoisomerase inhibitors | |
| Saleh et al. | Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy | |
| Germano et al. | Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines | |
| Czyż et al. | PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas | |
| Chen et al. | The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action | |
| Imanishi et al. | Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines | |
| de Castro e Gloria et al. | Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells | |
| O’Brien et al. | Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer | |
| Nasilowska-Adamska et al. | FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia | |
| Cetin et al. | The DNA damaging revolution | |
| D’Arcangelo et al. | The role of PARP in DNA repair and its therapeutic exploitation | |
| Bacalini et al. | A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis | |
| Messikommer et al. | RNA targeting in acute myeloid leukemia |